Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2010
This article has no abstract
Epistemonikos ID: 58ba5bf4841dae8cdca57a9b25e37f9ff3513580
First added on: May 11, 2020